Skip to main content

Table 5 Multivariate analysis for patients receiving immunotherapy (n = 5807)

From: Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis

  Hazard Ratio 95% Confidence Interval p-value
Sex Male 1.00 Ref < 0.0001
Female 0.79 0.75–0.84
Age 18–59 1.00 Ref < 0.0001
60–69 1.08 1.01–1.17
70–79 1.14 1.05–1.24
80+ 1.26 1.09–1.46
Comorbidity 0 1.00 Ref < 0.0001
1 1.15 1.07–1.23
> 2 1.25 1.12–1.40
Histology Adenocarcinoma 1.00 Ref < 0.0001
Non-adenocarcinoma 1.15 1.06–1.23
Race White 1.00 Ref 0.012
Non-white 0.89 0.82–0.98
Insurance Uninsured 1.00 Ref 0.079
insured 0.86 0.72–1.02
Facility Type Academic 1.00 Ref < 0.0001
Nonacademic 1.26 1.18–1.34
Radiation No Radiation 1.00 Ref < 0.0001
EBRT 1.37 1.29–1.46
SRT 0.78 0.66–0.93